Abbott, Insulet Partner on Automated Insulin Delivery System

Abbott and Insulet Corporation, a developer of tubeless insulin pump technology with its Omnipod Insulin Management System (Omnipod System), are partnering to integrate Abbott’s world-leading¹ glucose sensing technology with Insulet’s next-generation tubeless system, the Omnipod Horizon Automated Insulin Delivery (AID) System (Omnipod Horizon System), to offer personalized automated insulin delivery and care for people living with diabetes.
 
Controlled through an app on a user’s personal smartphone device—a unique feature that will be offered with the Omnipod Horizon System—the integrated platform will consist of the trusted tubeless insulin delivery Pod and Abbott’s next-generation FreeStyle Libre sensor. Through a simple, intuitive design, glucose data from the sensor will be sent directly to the Pod that is embedded with an algorithm to automatically adjust insulin delivery—without the need for an additional device, connection or tubing. This integrated system will be designed to always remain in automated insulin delivery mode and can be controlled through an app on a user’s personal smartphone to manually take a dose of fast-acting insulin, or bolus, before meals for optimal performance. Additionally, the integrated platform is expected to be the first combined system with a fully disposable wearable sensor and pump. 
 
“Abbott is focused on creating future-forward health technologies that simplify how people living with diabetes manage their condition so they can live their best lives,” said Jared Watkin, senior vice president, Diabetes Care, Abbott. “As diabetes care becomes more interoperable, we’re developing more connected approaches to improve care. Through this partnership, Abbott and Insulet will offer an integrated digital health platform that is simple and accurate and will provide a best-in-class user experience.”
 
“We are excited to expand our partnership with Abbott by building on our consumer-centric Omnipod Horizon platform, which offers unparalleled simplicity, accuracy, and now sensor choice for consumers,” said Shacey Petrovic, President and Chief Executive Officer, Insulet. “As interoperability becomes increasingly important, our approach to automated insulin delivery will change the future of blood glucose management by offering consumers greater choice in algorithms, sensors and overall experience. This collaboration furthers our shared vision to help our consumers put diabetes in the background, so they have more freedom to enjoy life.”
 
This connected care solution will integrate both the Omnipod Horizon System and FreeStyle Libre sensor data, offering a seamless option that will fit easily into the lives of people with diabetes. With both Insulet’s and Abbott’s ability to sell its products through the pharmacy, users of the integrated platform will benefit from ease of obtaining supplies with an innovative pay-as-you-go model.

References
¹ Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre system compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.